Back

Investigation of the prevalence of cardiac amyloidosis among patients with echocardiographically verified myocardial hypertrophy of unknown etiology

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: ePosters in myocardial disease - hypertrophic cardiomyopathy (1) Hypertrophic Cardiomyopathy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Nina Gataric

University Clinical Center of Serbia, Belgrade (Serbia)

6 More presentations in this session

Presentation thumbnail
Review of variants of uncertain significance in hypertrophic cardiomyopathy: a single-center multi-ethnic population experience
Doctor B. Chung (Kuching, MY)
Abstract Slides Video
Presentation thumbnail
Understanding the patient burden in transthyretin cardiac amyloidosis is significantly improved with continuing medical education
Doctor C. Rohani-Montez (London, GB)
Abstract Slides Video
Presentation thumbnail
Diagnostic performance of right ventricle wall thickness, strain, and their ratio in differentiating Fabry cardiomyopathy from wild-type transthyretin cardiac amyloidosis
Doctor E. Mata (Creixomil, PT)
Abstract Slides Video
Presentation thumbnail
Change of 3D echocardiographic parameters in obstructive hypertrophic cardiomyopathy during mavacamten treatment
Doctor R. Sepp (Szeged, HU)
Abstract Slides Video
Presentation thumbnail
Assessment of changes in right-sided cardiac echocardiographic parameters in obstructive hypertrophic cardiomyopathy during mavacamten treatment
Doctor R. Sepp (Szeged, HU)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in myocardial disease - hypertrophic cardiomyopathy (1)

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
High prevalence of cardiac amyloidosis with increasing age
thumbnail
Congress Presentation
Cardiac transthyretin amyloidosis in patients with conduction system disease
thumbnail
Congress Presentation
True prevalence of transthyretin cardiac amyloidosis in an unselected heart failure with preserved ejection fraction cohort

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources